Polypharmacology across inflammatory and immune pathway proteins

Polypharmacology across inflammatory and immune pathway proteins refers to a therapeutic strategy rather than a single biological molecule. It involves the use of drugs designed to interact with multiple targets within the complex network of immune signaling to achieve superior efficacy compared to highly selective single-target agents (Nature Reviews Drug Discovery, 2019). This approach is particularly prominent in the development of Janus kinase (JAK) inhibitors, which often target multiple JAK isoforms (JAK1, JAK2, JAK3, and TYK2) to block a broad spectrum of pro-inflammatory cytokines (PubMed, PMC6517033). By modulating several nodes in a pathway, polypharmacological agents can overcome the biological redundancy that often leads to drug resistance in chronic inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease (Journal of Medicinal Chemistry, 2021). While effective, this broad activity necessitates careful management of safety profiles, as inhibiting multiple immune pathways can increase the risk of opportunistic infections and other systemic adverse effects (NIH, StatPearls).

Other names

Multi-target pharmacologyNetwork pharmacologyPolypharmacological immune modulationMulti-kinase inhibition

Simultaneous modulation of multiple signaling proteins, such as various Janus kinase (JAK) isoforms or cytokine receptors, to disrupt interconnected inflammatory cascades.